ANIK

Business Context and Reporting Period

Company: Anika Therapeutics, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2006
Business Overview: Anika develops, manufactures, and commercializes therapeutic products based on hyaluronic acid (HA) for tissue protection and healing. Key products include ORTHOVISC (osteoarthritis), AMVISC/STAARVISC (ophthalmic viscoelastics), and HYVISC (equine osteoarthritis). The company also has products in development, including a cosmetic tissue augmentation (CTA) filler and INCERT (anti-adhesive).

Key Financial Metrics

Margins: Product gross profit margin was 51.4% in Q1 2006, compared to 47.3% in Q1 2005. The effective tax rate was 41.3% in Q1 2006 versus 40.4% in Q1 2005.

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased 4.6% year-over-year, primarily driven by a 57.4% drop in licensing and contract revenue. This decline is due to the absence of $918,354 in contract revenue recognized in Q1 2005 related to the terminated OrthoNeutrogena agreement.
• Product Revenue Growth: Product revenue increased 10.4% to $6.27 million. Growth was led by HYVISC (+35.6%), ORTHOVISC (+10.0%), and Ophthalmic products (+6.1%).
• Net Income Decrease: Net income fell 26.7% to $880,749. This was impacted by the loss of contract revenue and a new non-cash stock-based compensation expense of $382,537 resulting from the adoption of SFAS 123R.
• Cash Flow Shift: Operating cash flow turned negative ($475,821 used) compared to positive ($928,832 provided) in the prior year. This was caused by increases in accounts receivable and inventory, and decreases in accounts payable and accrued expenses.
• Expense Increases: Selling, general, and administrative (SG&A) expenses rose 38.5% largely due to the new stock-based compensation accounting standard. R&D expenses decreased 10.2% due to the completion of a pivotal clinical trial in the prior year.

Guidance, Outlook, and Risks

• Outlook: Management expects international sales of ORTHOVISC to grow in 2006 due to market penetration in Turkey and new markets. U.S. sales of ORTHOVISC are expected to see a more regular order flow as distributor inventory levels normalize. Ophthalmic product sales are expected to increase in 2006. Conversely, HYVISC sales are expected to decrease in 2006 based on current customer orders.
• Regulatory & Reimbursement: The company received CE marking approval for its CTA product in Q1 2006. For ORTHOVISC, reimbursement in physician offices continues to rely on a miscellaneous J-code for the remainder of 2006, which management believes may limit utilization compared to a unique code. A coding decision for 2007 is expected in the second half of 2006.
• Capital Expenditures: The company expects to increase capital expenditures in 2006 to complete manufacturing facility upgrades and equipment for the CTA product, with total costs estimated at approximately $3.5 million.
• Risks: Key risks include dependence on key customers (four customers represented 89.5% of product revenue in Q1 2006), reimbursement challenges for ORTHOVISC, and the success of clinical trials for new products.

Investor Verification Checklist

• Customer Concentration: Verify the stability of relationships with top customers, specifically Bausch & Lomb (43.2% of product revenue) and Depuy Mitek (13.5% of product revenue).
• Reimbursement Status: Monitor the CMS decision on J-coding for ORTHOVISC expected in late 2006, as this is a critical driver for U.S. sales growth.
• Inventory Levels: Review the increase in inventory ($3.5M vs $3.3M) and the company's ability to convert this into sales without obsolescence, particularly for HYVISC where sales are expected to decline.
• CTA Commercialization: Track progress in securing a worldwide distribution partner for the CTA product following its CE marking approval.
• Stock-Based Compensation: Assess the ongoing impact of SFAS 123R on future earnings, with approximately $2.8 million of unrecognized compensation cost remaining.